Akums Drugs' AA (stable) long-term rating and A1 short-term rating are maintained by ICRA, due to robust CDMO growth, minimal debt levels, and good liquidity. However, the company faces competition pressures and rising raw material costs as challenges.

Akums Drugs and Pharmaceuticals Ltd has received positive reviews from ICRA, maintaining strong credit ratings for working capital limits and initiating a new commercial paper program. The company's CDMO revenue increased by 7% YoY to Rs. 2,533 crore in the first nine months of FY26 due to growth in volume and a significant EUR 100M contract, enhancing liquidity.

Akums Pharma has successfully breached its resistance trendline, indicating a potential positive shift in its price movement. The stock's pattern of higher lows, followed by a week of consolidation, and a surge in trading volume suggests that investors are increasingly accumulating the shares.